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One of the major challenges in successful treatment of advanced stage high-grade serous ovarian cancer (HGSOC) 
is the development of platinum-based chemotherapy resistance. Identification of key genes that modulate 
platinum-response may improve patient selection or result in the development of novel targeted strategies to 
overcome platinum resistance. In this study, we applied functional genomic mRNA (FGmRNA) profiling on a large 
set of HGSOC patients (n=422, all stage III-IV and treated with platinum-based chemotherapy) to identify genes 
that were associated with progression free survival (PFS). Expression of 303 genes was significantly associated 
with PFS. Highly expressed genes that were significantly associated with poor PFS included MAD1L1, PRKD1, 
SUPT20H, NFKBIB, MMP24-AS1 and IGF-2R. Genes associated with poor PFS were enriched in biological 
processes with GO terms cell cycle, chromosome, mitosis, catabolic and microtubule-related processes. Highly 
expressed genes like MPPE1, BAG2, NEDD8, CASP2, MRSP11, EVI5, NFX1 and PARP1 were significantly 
associated with better PFS. GO terms linked to cell locomotion activity, transmembrane and vesicle-mediated 
transport, DNA damage repair and cytoplasmic processes were enriched for genes associated with better PFS. 
In conclusion, by applying FGmRNA-profiling, we identified genes associated with PFS (i.e. chemoresponse) and 
their related biological processes in a clinically well-defined subset of HGSOC patients treated with platinum-
based chemotherapy. 




High-grade serous ovarian cancer (HGSOC) patients predominantly present with advanced stage (stage III and 
IV) disease. These patients undergo debulking surgery in combination with platinum-based chemotherapy1. 
Although the majority of patients respond very well to standard chemotherapy with only 20-30% patients 
inherently resistant, 70-90% of responding patients relapse with resistant diseases2,3. Currently, the acquisition 
of chemotherapy resistance is one of the major hurdles for the successful treatment of HGSOC patients. 
Consequently, HGSOC remains the most lethal gynecological malignancy with a five year survival rate of 
25–30%4. Therefore, gaining insight into the mechanisms and factors associated with platinum resistance 
would enable us to develop treatment strategies to overcome chemotherapy resistance and improve the clinical 
outcome.
Gene expression analyses of ovarian cancers have been performed for more than a decade. Several studies 
have been performed to identify the subgroups of ovarian cancer patients regarding different survival pattern 
or response to platinum-based chemotherapy5–9. Besides mRNA expression data, multiple genomics-based 
data were generated on large HGSOC patient cohorts to integrate expression profile with other genomics data 
like somatic copy number alterations (SCNA), DNA methylation and other features10–12. Taking advantage of 
publicly available expression datasets, several studies were recently conducted to identify in-silico chemotherapy 
response predictive profiles that could be used in the clinic for upfront selection of patients13–15. However, none 
of the expression-based prognostic profiles for treatment response of HGSOC patients have yet made their way 
to clinic. 
HGSOC is a prototypical cancer with a very high degree of genomic instability that is distinguished by aneuploidy 
and large burden of SCNAs16,17. These genomic alterations can translate into downstream effects such as 
alterations in gene expression levels (activation of a gene or pathway)18. These genomic alterations and their 
downstream molecular effects will have a complex impact on the tumor behavior and treatment response. The 
recently introduced method of functional genomic mRNA-profiling (FGmRNA-profiling) demonstrated that most 
SCNA has an effect on gene expression levels. However, this effect is often very subtle and will commonly be 
overshadowed by many other, non-genetic factors (e.g. physiological or experimental factors) that are considered 
to be irrelevant for tumor behavior or treatment response19. This could be a possible explanation for the fact 
that currently none of the gene expression based profiles could make their way in clinic within the context of 
HGSOC. FGmRNA-profiling is capable of correcting gene expression data and allows for an enhanced view of the 
downstream effects of SCNAs on gene expression levels in relation to tumor phenotypes.
Defining a response endpoint for patients is a critical parameter to identify genes associated with response to 
platinum-based chemotherapy. Assessment of tumor shrinkage, objective response (OR) and time to disease 
progression have been considered as major endpoints of any clinical trial for evaluation of HGSOC patients’ 
response towards platinum-based chemotherapy20. Based on the retrospective analysis of clinical studies in 
ovarian cancer, PFS has been considered as a good primary endpoint in the first-line setting where improvement 
in PFS is often followed by overall survival (OS) of HGSOC patients21. 
In the present study, we applied FGmRNA-profiling on a large expression dataset of clinically well-defined 
advanced stage HGSOC patients (n=422) to identify genes associated with PFS. All patients received first-line 




from platinum-based chemotherapy. Also, these genes and related pathways might guide the development of 
novel targeted strategies to overcome platinum resistance. 
Material and Methods
Data collection and preprocessing
We collected publicly available raw microarray expression data from two datasets containing tumor samples of 
patients with late stage, HGSOC for which PFS data was available in combination with residual disease status 
after primary surgery and age at diagnosis. The site of the primary biopsy had to be the ovary. In addition, only 
patients were selected that had been treated with platinum-based chemotherapy. Samples had to be hybridized 
to the Affymetrix HG-U133A or HG-U133 Plus 2.0 platforms. The first dataset included was the ovarian serous 
cystadenocarcinoma set from The Cancer Genome Atlas (TCGA)10. We were able to extract 335 patients with the 
aforementioned inclusion criteria (Supp. Table 1). The second dataset included was Australian Ovarian Cancer 
Study Group dataset (GSE9899)8 from which we were able to include 87 patients who met the inclusion 
criteria (Supp. Table 1). Hence, in total we had 422 HGSOC patients included for the analysis (Table 1). Raw 
data CEL files were downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/) or collected from the 
Gene Expression Omnibus (GEO, accession number GSE9899). Pre-processing and aggregation of CEL files was 
performed with Affymetrix Power Tools version 1.15.2, using apt-probe set-summarize and applying the robust 
multi-array average (RMA) algorithm, using the latest Affymetrix GeneChip Array CDF layout files.
Sample quality control
Principal Component Analysis (PCA) on the sample correlation matrix was used for quality control. The first 
principal component (PCqc) of such an expression microarray correlation matrix describes nearly always a 
constant pattern that dominates the data, explaining around 80–90% of the total variance. This pattern can be 
Table 1. Patient characteristics of meta-analysis cohort (n=422)
Characteristic Category or Measure n or value Percentage
Age (years) Median (range) 58 (30-87)
Overall survival (days) Median (range) 848 (0-4980)
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regarded as probe-specific or platform specific variance, independent of the biological sample hybridized to the 
array9,22. The correlation of each individual microarray expression profile with this PCqc can be used to detect 
outliers, as arrays of lesser quality will have a lower correlation with the PCqc. All expression profiles showed 
high correlation (R>0.8).
Functional genomic mRNA profiling
We developed a method called FGmRNA-profiling that corrects gene expression data (i.e. mRNA expression 
data) for major, non-genetic, factors (e.g. physiological, metabolic, cell-type-specific and experimental factors)19. 
We observed that the residual gene expression signal (i.e. FGmRNA signal) correlated strongly with SCNAs 
in cancer samples. In other words, with FGmRNA-profiling we captured the downstream effect of genomic 
alterations at gene expression levels. For a detailed description of FGmRNA-profiling we referred to Fehrmann et 
al.19 and  generated FGmRNA-profiles for all 422 HGSOC patients.
Association with PFS
To assess the association of the FGmRNA signal of individual genes with PFS, we performed multivariate Cox 
regression analyses with time to tumor progression and time to recurrence as outcome variables, and age, 
debulking status as covariates (all extracted from TCGA and GSE9899). To minimize false positive or negative 
associations due to batch effects present between the two datasets included in this analysis, we calculated 
association statistics per dataset. Hazard ratios were combined and p-values were calculated according to the 
generic inverse-variance approach with random-effects model23. 
Determining genomic regions associated with PFS
We hypothesized that specific genomic regions with SCNAs might be associated with PFS. These associated 
genomic regions might contain the genes responsible for platinum resistance. Under this hypothesis genomic 
regions should contain genes that show on average more significant association with PFS that one would expect 
based on chance. To assess the association of genomic regions with PFS we applied a sliding window approach. 
The first step was to calculate the association of each individual gene with PFS as described above. Next, we 
sorted all genes (with their p-values) according to their genomic mapping. Subsequently, we applied a sliding 
window to the sorted p-values. We set the sliding window to a fixed interval of 1MB base pairs. P-values of genes 
that map within this genomic region of 1MB base pairs were grouped into a set. We determined a combined 
p-value for this set of genes by applying Liptak trend method to the p-values (z-transformed p-values keeping 
intact the direction of association)24. The sliding window proceeded to the neighboring mapping gene until all 
genes were at the center of the sliding window once. The sliding window was applied to all chromosomes 
separately. This method resulted in a vector where each element described the combined p-values (strength of 
association with PFS) for a specific genomic region. To determine the null distribution of this sliding window 
approach, we applied a multivariate permutation test [1,000 permutations with a false discovery rate (FDR) of 
5% and confidence of 80%]. Per permutation step we randomly assigned a genomic location to each individual 
gene and repeated the sliding window approach as described above. This multivariate permutation tests resulted 
in a list of significant associated genomic regions that contained no more than 5% false discoveries with a 
confidence level of 80%. 
Functional annotation analysis of enriched significant genes
We considered an individual gene significantly associated with PFS if the significance level for that gene was 




the sliding window approach as described above. The DAVID Gene Functional Classification Tool25 (http://david.
abcc.ncifcrf.gov) was performed with only genes significantly associated with PFS as well as with its genomic 
region on the selected genes (303 genes) to identify gene ontology biological processes (GOBP) using default 
parameters and using all currently functionally annotated known genes for human as reference background. 
GOBP terms with a p<0.05 and FDR<0.05 were considered significant for enrichment. The enriched GOBP 
terms were clustered using REVIGO26 to depict a representative subset of GOBP categories.
Cytoband analysis of enriched significant genes
The GATHER27 (http://gather.genome.duke.edu) cytoband analysis was only performed with genes that were 
significantly associated with PFS as well as with its genomic region (as describe above) to identify the most 
significantly PFS-associated genomic location of genes clusters using default parameters of GATHER. 
Determining the copy number load index and its association with PFS and individual genes
As mentioned above, we have previously shown that FGmRNA-profiles correlated strongly with SCNAs in cancer 
samples19. In this study, we used the FGmRNA-profiles to summarize the total level of SCNAs in a given HGSOC 
tumor in a single univariate measure, which we call the CNL-index. To determine the CNL-index per sample, 
we first sorted all genes according to their genomic mapping. Subsequently, we applied a sliding window to 
the sorted FGmRNA-signals. We set the sliding window to a fixed size of 500K base pairs. Genes that mapped 
within this genomic region of 500K base pairs were grouped into a set designated ‘A’. The rest of the genes, 
localized elsewhere on the genome, were grouped into a set ‘B’. The functional aneuploidy measure for the given 
genomic 500K base pair region is the value of the Student’s t statistic comparing sets A and B. The sliding 
window proceeded to the neighboring mapping gene until all genes were at the center of the sliding window 
once. The sliding window was applied to all chromosomes separately. This method resulted, per individual 
sample, in a vector, where each element described the functional aneuploidy measure for a specific genomic 
region. The sum of the absolute functional aneuploidy measures (i.e. T-statistics) resulted in the CNL-index. The 
association with PFS was determined by multivariate Cox regression as described above. Correlation between 
individual genes (FGmRNA signal) and CNL-index was determined according to Spearman Rho. 
Results
Functional mRNA genomics profiling associated with chemotherapy response in HGSOC
We performed a genome-wide association study between FGmRNA expression levels and PFS with 422 
advanced stage HGSOC patients who received platinum-based chemotherapy (Figure 1A). Out of 22277 probes, 
1383 probes (6.2% of total probes), representing 1189 genes were significantly associated (p<0.05) with PFS. 
Among these 1383 significant probes, enhanced expression of 591 probes was associated with worse PFS. 
Enhanced expression of the other 792 probes was associated with a prolonged PFS (Figure 1B). 
Genomic enrichment in relation to chemoresponse in HGSOC
In addition to determining the relation between probe expression and PFS, an alternative approach was used. 
We hypothesized that specific genomic regions with SCNAs might be associated with PFS. Under this hypothesis 
genomic regions should contain genes that show on average more significant association with PFS than would be 
expected based on chance. To assess the association of genomic regions with PFS we applied a sliding window 
approach based on the p-values of probes from the FGmRNA profiled data (see M&M for further explanation). 









Figure 1.  Identification of PFS associated genes in HGSOC patients. (A) Schematic representation of strategy to identify 
genes associated with PFS in HGSOC patients (n=422). (B) Manhattan plot of probes over chromosomal regions that were 
associated with PFS in FGmRNA profiled expression dataset. (C) Manhattan plot of probes over chromosomal regions that 
were associated with PFS after applying genomic region meta-analysis sliding window method. Green dots represent those 
probes that passed the cut-off for chromosomal enriched genes based on the FDR (<0.05) with 80% of confidence interval. 
(D) Venn diagram showing the common 358 probes obtained after cross-comparison of FGmRNA profiled PFS associated 
genes and genomic region enriched genes. (E) Sorted association of highly expressed PFS associated genes with either worse 




This analysis resulted in the identification of over 1500 PFS-associated genomic regions containing 2431 probes 
(Figure 1C).
Next, we combined the PFS-associated probes from the genome-wide association analysis as described above 
(1383 probes) with the probes found in the PFS-associated genomic regions (2431 probes). This analysis 
revealed 358 overlapping probes, representing 303 unique genes that were significantly associated with PFS 
(p<0.05) in HGSOC patients (Figure 1D). Among these 303 genes, enhanced expression of 113 genes (37.3%) 
A 
B 
Figure 2. Gene Ontology (GO) term enrichment of genes that were significantly associated with PFS in HGSOC patients. 
(A) GO terms enriched for genes whose high expression was associated with worse PFS in HGSOC patients. Bars represent 
the number of genes and line represents enrichment p-value. (B) GO terms enriched for genes whose high expression was 
associated with better PFS. Bars represent the number of genes and line represents enrichment p-value.
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was associated with worse PFS, whereas enhanced expression of the other 190 genes (62.7%) was associated 
with better PFS (Figure 1E).
To gain insight into the chromosomal location that significantly associated with PFS, we performed cytoband 
analysis by GATHER using the 303 individual PFS associated genes27. Enrichment of the 113 genes associated 
with worse PFS was found on chromosomal location Chr5.q31, Chr7.p22, Chr16.p13, Chr17.q11 and Chr19.
p13 (Table 2A), whereas enrichment of the 190 genes associated with better PFS was found on chromosomal 
location Chr1.p22, Chr9.q34, Chr14.q21, Chr15.q25 and Chr18.p11 (Table 2B). 
Biological process annotation of chemoresponse associated genes
The 303 genes were ranked based on their association with PFS. The top significant genes were MAD1L1, 
PRKD1, SUPT20H, NFKBIB, MMP24-AS1 and IGF-2R, which were associated with poor PFS (Z score ≥3.5; 
Figure 1E). MPPE1, BAG2, NEDD8, CASP2, MRSP11, EVI5, NFX1 and PARP1 were at the bottom of 303 
genes list and were the most significant genes associated with better PFS (Z score ≤ -3.5; Figure 1E). 
To gain more insight into the biological relevance of the 113 genes related with worse PFS, gene ontology (GO) 
enrichment was performed by DAVID25. GO terms enriched for these genes were chromosomes, cell-cycle related, 
RNA and macromolecule catabolic process; microtubule-related processes (Figure 2A and Table 3A). GO terms 
that enriched for the 190 genes associated with better PFS were cell leading edge, cytosol, hydrolase activity, 
protein metabolism, negative regulation of DNA damage stimuli, phagocytosis and vacuole transportation, and 
cytoplasmic vesicles (Figure 2B and Table 3B). Among the top 10 GO terms, more nucleus-related GO terms 
seem to be associated to poor PFS (6/10) than that to better PFS of patients (2/10). In contrast, there is a 
trend of more cytoplasmic GO terms being related to better PFS (8/10) than to poor PFS (3/10) (p=0.07). 
Association between genomic instability and PFS-associated genes
We have previously shown that FGmRNA-profiles correlated strongly with SCNAs in cancer samples19. Here, 
we used FGmRNA-profiles to get a single univariate measure that represents the total level of SCNAs in a 
given HGSOC tumor that we called the copy number load index (CNL-index; see M&M for further explanation). 
We have previously shown that the functional aneuploidy measurement (referred as CNL-index in this study) 
can be used to calculate the degree of genomic instability in many tumor types19. Hence, a high CNL-index is 
related to higher genomic instability. To determine the genomic instability for these HGSOC patients (n=422), 
we calculated the CNL-index for each of the samples and analyzed its association with PFS, as described in 
the method section. In this homogenous clinicopathological group of HGSOC patients using debulking surgery 
and age as covariates, we found that a higher CNL-index was related to better PFS (HR=0.012 (0.0001-
0.89), p=0.044). Next, we determined the correlation between the FGmRNA expression level for each of the 
303 PFS-associated genes and the CNL-index. Genes related to better PFS (HR<1) had a positive correlation 
with higher CNL-index, whereas genes related to poor PFS (HR>1) were correlated with low CNL -index (R = 
-0.5545) (Figure 3).
Discussion
Resistance to platinum-based chemotherapy platinum limits successful treatment of HGSOC patients. Therefore, 
identification of key chemoresponse genes for platinum therapy would be beneficial for such patients. Based on 
FGmRNA-profiling, we identified 303 genes significantly associated with PFS in a clinically well-defined set of 




whereas enhanced expression of the other 190 genes was associated with better PFS. This knowledge may be 
helpful in the future to identify patients at risk for platinum-based chemotherapy resistance and eligible for novel 
treatment strategies to overcome platinum resistance. 
Among higher expressed genes significantly associated with poor PFS, we found MAD1L1, PRKD1, SUPT20H, 
NFKBIB, MMP24-AS1 and IGF-2R. Some of these genes have been reported in relation to chemoresistance, 
either in ovarian cancer or other cancer types. Mitotic arrest deficient 1 (MAD1 or MAD1L1), a protein of the 
mitotic spindle assembly checkpoint, significantly correlated with poor prognosis in chemotherapy-treated lung 
cancer, breast cancer and colon cancer patients28,29. In colon cancer, MAD1 facilitates doxorubicin resistance 
through attenuating the apoptosis pathway and reducing the production of reactive oxygen species (ROS) by 
inhibiting mitochondrial function30. Also, being an antagonist of c-MYC, MAD1 has been demonstrated to 
modulate TRAIL sensitivity of tumors by the MYC/MAX/MAD network31. SUPT20H, also known as FAM48A, 
was reported in relation to poor prognosis and chemoradioresistance in cervical cancer32. Surprisingly, NFKBIB, 
an endogenous inhibitor of NKFB pathway activation, was found significantly associated with poor prognosis33, 
whereas NFKB pathway activation is frequently linked to ovarian cancer initiation and progression. Hence, 
involvement of NFKBIB needs further functional validation and mechanistic insight for proving its role in 
chemoresistance in ovarian cancer. IGF-2R is considered a multifunctional receptor in carcinogenesis34–36. The 
tumor suppressive effect of IGF-2R is lost in many cancer types due to mutation or loss of heterozygosity 
A 
B 
Table 2. Cytoband enrichment analysis of genes that were significantly associated with worse PFS (A) 
or with better PFS (B) in HGSOC patients
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(LOH)34. However, recent evidence showed high expression of IGF-2R in ovarian cancer initiating cells to be 
associated with YAP/TEAD pathway activation, which induces chemoresistance35. Our meta-analysis discovered 
several interesting druggable kinases like PRKD1 and BRD4. High expression of these kinases was linked to 
poor PFS in platinum-treated HGSOC patients. PRKD1 is a well-studied member of protein kinase family that 
is known for its role in tumorigenesis, metastasis and invasion in breast and pancreatic cancer37–40. Although 
pan-PRKD inhibitors demonstrated anti-tumor activity in vitro as well as in vivo in various tumor type40–43, 
the role of PRKD1 and its inhibitor in ovarian cancer is unknown. BRD4 is a known BET bromo-domain 
family kinase involved in chromatin remodeling44. In concordance with our study, recently BRD4 amplification 
has been shown to correlate with worse survival with HGSOC patients45. Available bromo-domain inhibitors 
showed remarkable efficacy in ovarian cancer cells by inhibition of tumor growth via targeting Myc and FoxM1 
transcriptional program45,46. These findings provide a rationale for future testing of these kinase inhibitors in 
HGSOC models, either alone or in combination with platinum-based therapy to overcome drug resistance. We 
also found genes like MPPE1, BAG2, NEDD8, CASP2, MRSP11, EVI5, NFX1 and PARP1 whose expression 
levels were significantly associated with better PFS. Apoptosis pathway related genes like BAG2 and CASP2 
have been shown to overcome chemoresistance and induce apoptosis in various types of tumor cells including 
ovarian cancer 47–49. Therefore, these genes might be used to identify HGSOC patients upfront for platinum-
based chemotherapy.
HGSOC is known as a highly genomic instable tumor type with defects in DNA damage repair (DDR) 
pathways10. Therefore, we determined the CNL-index representing genomic instability for each tumor sample. 
Overall, a higher degree of genomic instability was related with a better PFS. These results are in agreement 
Figure 3. Scatter plot of significantly enriched PFS associated genes (303) and their association with copy number 
load (CNL-) index. X-axis represents the hazard ratio of PFS associated genes in HGSOC patients and Y-axis represents 
the spearman correlation of each gene with CNL-index. Purple line shows overall correlation between hazard ration and 
spearman correlation (R=-0.5545). Top ranked genes are represented by red diamonds with bold gene names and rest of 




with previous findings describing a positive correlation between genomic instability, calculated based on same CNL-
index methodology, and survival benefit in HGSOC treated with platinum-based chemotherapy19. Another study 
calculated genomic instability based on loss of heterozygosity (LOH) and copy number changes using single 
nucleotide polymorphism array data from three different HGSOC cohorts50. Similar to our study, they found 
a significant positive correlation between LOH burden and PFS. Furthermore, a comparable relation between 
genomic instability expressed as LOH burden and survival benefit was observed in triple-negative breast cancer, 
a tumor type that has many similarities to HGSOC50. Moreover, we found that high expression of DDR-related 
BRCA2 positively correlated with lower PFS of HGSOC patients. This finding is in agreement with the study of 
Mankoo et al. who also used TCGA genomics data for finding patient survival related profiles51. They did not 
find BRCA1 to be predictive for PFS, which is in line with our results. BRCA2 mutations in HGSOC, mainly 
A 
B 
Table 3. Gene ontology (GO) terms enriched for genes whose high expression were significantly associated with worse 
PFS (A) or with better PFS (B)
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resulting in protein inactivation10,12, have been reported to be stronger associated with better survival, improved 
chemotherapy response, and higher genomic instability compared to those with BRCA1 mutation or BRCA1/2 
wild type52–54. 
In conclusion, by applying mRNA expression data analysis approach (FGmRNA-profiling), we report genes that 
are highly associated with PFS in a clinically well-defined subset of HGSOC patients treated with platinum-based 
chemotherapy. Further, our meta-analysis of HGSOC data provides insight into biological processes involved 
in a better or worse response and their association with genomic instability. Future research should focus on 
assessment of identified prognostic genes for their potential relevance in terms of novel therapeutic strategies to 
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TCGA (n=335) Tothill et al (n=87)
n or value Percentage n or value Percentage
Age (years) Median (range) 58 (30-87) 59 (33-80)
Overall survival (days) Median (range) 847 (25-4623) 870 (0-4980)
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Supplementary Table 2. Top 100 enriched and PFS-associated probes list
Rank ID Gene symbol Gene title Chromosomal location Z score Significance
 1 204857_at MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) chr7p22 4.789 1.68E-06
 2 206764_x_at MPPE1 metallophosphoesterase 1 chr18p11.21 -4.534 5.78E-06
 3 217705_at PRKD1 protein kinase D1 chr14q11 4.399 1.09E-05
 4 209406_at BAG2 BCL2-associated athanogene 2 chr6p12.1-p11.2 -4.255 2.09E-05
 5 201840_at NEDD8 neural precursor cell expressed, developmentally down-regulated 8 chr14q12 -4.113 3.91E-05
 6 208050_s_at CASP2 caspase 2, apoptosis-related cysteine peptidase chr7q34-q35 -4.053 5.06E-05
 7 221774_x_at SUPT20H suppressor of Ty 20 homolog (S. cerevisiae) chr13q13.3 3.805 0.00014
 8 214062_x_at NFKBIB nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta chr19q13.1 3.770 0.00016
 9 211595_s_at MRPS11 mitochondrial ribosomal protein S11 chr15q25 -3.763 0.00017
10 221953_s_at MMP24-AS1 MMP24 antisense RNA 1 chr20q11.22 3.715 0.00020
11 209717_at EVI5 ecotropic viral integration site 5 chr1p22.1 -3.683 0.00023
12 202584_at NFX1 nuclear transcription factor, X-box binding 1 chr9p13.3 -3.637 0.00028
13 201393_s_at IGF2R insulin-like growth factor 2 receptor chr6q26 3.541 0.00040
14 208644_at PARP1 poly (ADP-ribose) polymerase 1 chr1q41-q42 -3.537 0.00041
15 206363_at MAF v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) chr16q22-q23 3.500 0.00047
16 218991_at HEATR6 HEAT repeat containing 6 chr17q23.1 -3.460 0.00054
17 206652_at ZMYM5 zinc finger, MYM-type 5 chr13q12 3.431 0.00060
18 216117_at EXOSC2 exosome component 2 chr9q34 -3.412 0.00065
19 201653_at CNIH cornichon homolog (Drosophila) chr14q22.2 -3.351 0.00081
20 209624_s_at MCCC2 methylcrotonoyl-CoA carboxylase 2 (beta) chr5q12-q13 3.329 0.00087
21 201748_s_at SAFB scaffold attachment factor B chr19p13.3-p13.2 -3.321 0.00090
22 200075_s_at GUK1 guanylate kinase 1 chr1q32-q41 -3.320 0.00090
23 202234_s_at SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) chr1p12 -3.315 0.00092
24 213082_s_at SLC35D2 solute carrier family 35, member D2 chr9q22.32 -3.311 0.00093
25 218210_at FN3KRP fructosamine 3 kinase related protein chr17q25.3 -3.259 0.00112
26 213007_at FANCI Fanconi anemia, complementation group I chr15q26.1 -3.247 0.00117
27 221979_at TOPORS-AS1 TOPORS antisense RNA 1 chr9p21.1 -3.220 0.00128
28 205909_at POLE2 polymerase (DNA directed), epsilon 2, accessory subunit chr14q21-q22 -3.183 0.00146
29 220207_at YIF1B Yip1 interacting factor homolog B (S. cerevisiae) chr19q13.2 3.179 0.00148
30 209076_s_at WDR45B WD repeat domain 45B chr17q25.3 -3.174 0.00150
31 213727_x_at MPPE1 metallophosphoesterase 1 chr18p11.21 -3.171 0.00152
32 213389_at ZNF592 zinc finger protein 592 chr15q25.3 -3.161 0.00157
33 205161_s_at PEX11A peroxisomal biogenesis factor 11 alpha chr15q26.1 -3.160 0.00158
34 222211_x_at SCAND2P SCAN domain containing 2 pseudogene chr15q25.2 -3.149 0.00164
35 212772_s_at ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2 chr9q34 -3.144 0.00166
36 209671_x_at TRAC T cell receptor alpha constant chr14q11 -3.141 0.00168
37 202324_s_at ACBD3 acyl-CoA binding domain containing 3 chr1q42.12 -3.119 0.00182
38 206141_at MOCS3 molybdenum cofactor synthesis 3 chr20q13.13 3.108 0.00188
39 204796_at EML1 echinoderm microtubule associated protein like 1 chr14q32 -3.102 0.00192
40 202053_s_at ALDH3A2 aldehyde dehydrogenase 3 family, member A2 chr17p11.2 3.086 0.00203
41 215011_at SNHG3 /// SNORA73A small nucleolar RNA host gene 3 (non-protein coding) chr1p36.1 3.060 0.00221
42 221365_at MLNR motilin receptor chr13q14-q21 3.049 0.00230
43 203017_s_at SSX2IP synovial sarcoma, X breakpoint 2 interacting protein chr1p22.3 -3.049 0.00230




Rank ID Gene symbol Gene title Chromosomal location Z score Significance
45 203463_s_at EPN2 /// EPN2-IT1 epsin 2 /// EPN2 intronic transcript 1 chr17p11.2 3.023 0.00251
46 208590_x_at GJA3 gap junction protein, alpha 3, 46kDa chr13q12.11 3.020 0.00253
47 204473_s_at ZNF592 zinc finger protein 592 chr15q25.3 -3.011 0.00260
48 203212_s_at MTMR2 myotubularin related protein 2 chr11q22 -3.002 0.00268
49 209094_at DDAH1 dimethylarginine dimethylaminohydrolase 1 chr1p22 -2.998 0.00272
50 212155_at RNF187 ring finger protein 187 chr1q42.13 -2.996 0.00274
51 203470_s_at PLEK pleckstrin chr2p13.3 -2.989 0.00280
52 202623_at EAPP E2F-associated phosphoprotein chr14q13.1 -2.981 0.00288
53 210544_s_at ALDH3A2 aldehyde dehydrogenase 3 family, member A2 chr17p11.2 2.978 0.00290
54 220408_x_at SUPT20H suppressor of Ty 20 homolog (S. cerevisiae) chr13q13.3 2.972 0.00296
55 207692_s_at ACAN aggrecan chr15q26.1 2.958 0.00310
56 203015_s_at SSX2IP synovial sarcoma, X breakpoint 2 interacting protein chr1p22.3 -2.946 0.00322
57 215070_x_at RABGAP1 RAB GTPase activating protein 1 chr9q34.11 -2.934 0.00334
58 201531_at ZFP36 ZFP36 ring finger protein chr19q13.1 2.931 0.00338
59 215747_s_at RCC1 regulator of chromosome condensation 1 chr1p36.1 2.925 0.00344
60 209143_s_at CLNS1A chloride channel, nucleotide-sensitive, 1A chr11q13.5-q14 -2.919 0.00351
61 210237_at ARTN artemin chr1p33-p32 -2.915 0.00355
62 220261_s_at ZDHHC4 zinc finger, DHHC-type containing 4 chr7p22.1 2.902 0.00371
63 202270_at GBP1 guanylate binding protein 1, interferon-inducible chr1p22.2 -2.895 0.00379
64 204387_x_at MRP63 mitochondrial ribosomal protein 63 chr13q12.11 2.886 0.00391
65 209058_at EDF1 endothelial differentiation-related factor 1 chr9q34.3 -2.882 0.00395
66 203628_at IGF1R insulin-like growth factor 1 receptor chr15q26.3 -2.834 0.00459
67 209392_at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 chr8q24.1 -2.821 0.00479
68 200881_s_at DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 chr9p13.3 -2.821 0.00479
69 219332_at MICALL2 MICAL-like 2 chr7p22.3 2.816 0.00487
70 47083_at C7orf26 chromosome 7 open reading frame 26 chr7p22.1 2.814 0.00489
71 204448_s_at PDCL phosducin-like chr9q12-q13 -2.811 0.00493
72 210839_s_at ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 chr8q24.1 -2.802 0.00508
73 212577_at SMCHD1 structural maintenance of chromosomes flexible hinge domain containing 1 chr18p11.32 -2.798 0.00515
74 207675_x_at ARTN artemin chr1p33-p32 -2.796 0.00518
75 204496_at STRN3 striatin, calmodulin binding protein 3 chr14q13-q21 -2.796 0.00518
76 219203_at EMC9 ER membrane protein complex subunit 9 chr14q11.2 -2.785 0.00535
77 217736_s_at EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1 chr7p22 2.781 0.00542
78 210605_s_at MFGE8 milk fat globule-EGF factor 8 protein chr15q25 -2.764 0.00571
79 202839_s_at NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa chr19p13.12 2.760 0.00578
80 201722_s_at GALNT1 N-acetyl-alpha-D-galactosamine:N-acetylgalactosaminyltransferase 1 (GalNAc-T1) chr18q12.1 -2.759 0.00579
81 211501_s_at EIF3B eukaryotic translation initiation factor 3, subunit B chr7p22.3 2.759 0.00580
82 213794_s_at NGDN neuroguidin, EIF4E binding protein chr14q11.2 -2.751 0.00594
83 212919_at DCP2 decapping mRNA 2 chr5q22.2 2.745 0.00605
84 212628_at PKN2 protein kinase N2 chr1p22.2 -2.732 0.00630
85 218555_at ANAPC2 anaphase promoting complex subunit 2 chr9q34.3 -2.729 0.00636
86 217730_at TMBIM1 transmembrane BAX inhibitor motif containing 1 chr2q35 -2.725 0.00644
87 204064_at THOC1 THO complex 1 chr18p11.32 -2.715 0.00663
Supplementary Table 2. Top 100 enriched and PFS-associated probes list (Continued)
Functional genomic mRNA profiling of HGSOC
7
163 
Rank ID Gene symbol Gene title Chromosomal location Z score Significance
 88 215236_s_at PICALM phosphatidylinositol binding clathrin assembly protein chr11q14 -2.714 0.00664
 89 217912_at DUS1L dihydrouridine synthase 1-like (S. cerevisiae) chr17q25.3 -2.712 0.00668
 90 218924_s_at CTBS chitobiase, di-N-acetyl- chr1p22 -2.710 0.00672
 91 209858_x_at MPPE1 metallophosphoesterase 1 chr18p11.21 -2.693 0.00708
 92 209051_s_at RALGDS ral guanine nucleotide dissociation stimulator chr9q34.3 -2.690 0.00714
 93 215281_x_at POGZ pogo transposable element with ZNF domain chr1q21.3 2.689 0.00717
 94 203464_s_at EPN2 /// EPN2-IT1 epsin 2 /// EPN2 intronic transcript 1 chr17p11.2 2.689 0.00717
 95 217806_s_at POLDIP2 polymerase (DNA-directed), delta interacting protein 2 chr17q11.2 2.688 0.00719
 96 218299_at C11orf24 chromosome 11 open reading frame 24 chr11q13 -2.685 0.00725
 97 203348_s_at ETV5 ets variant 5 chr3q28 -2.684 0.00727
 98 210128_s_at LTB4R leukotriene B4 receptor chr14q11.2-q12 -2.681 0.00734
 99 204551_s_at AHSG alpha-2-HS-glycoprotein chr3q27 -2.660 0.00783
100 202093_s_at PAF1 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) chr19q13.1 2.654 0.00795
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